The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared
to Placebo in patients with genetically proven CADASIL. In addition, a traditional approach
will be taken based on an evaluation of the separate risk and benefit domains in comparison
with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Ever Neuro Pharma GmbH
Collaborators:
idv Datenanalyse & Versuchsplanung X Clinical GmbH